Value communication oncology

Customer Situation

A pharmaceutical company active in oncology very recently established a German subsidiary and was preparing for an early benefit assessment. The company had no contacts to relevant stakeholders.

Our Solution

We established contacts with relevant key opinion leaders and organised an advisory board meeting in which our client received important impulses for the positioning of the drug in the early benefit assessment. In addition, we organised several stakeholder meetings including payers, among others. In these discussions, our client succeeded in at least partially dispersing concerns about the relatively high-priced drug.

Customer Benefit

With our support, our client was well prepared for the market access process in Germany and achieved the expected level of additional benefit. The final reimbursement price even exceeded our client’s expectations.